Allergists Affirm Safety of COVID-19 Vaccines for Most
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
The much-awaited remedy to the widespread transmission of SARS-CoV-2 comes with many logistical caveats.
Study authors investigated the persistence of immune response with a single-dose of inactivated Japanese encephalitis vaccine and the interchangeability with a live-attenuated vaccine in healthy children aged 1 to 15 years.
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.
Nurse practitioners (NPs) executed a 5-step vaccination program for homeless individuals in Miami-Dade County to help reduce the spread of infectious diseases.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
The 2018 to 2019 influenza vaccine effectiveness was about 40% to 60% for reducing pediatric influenza A-associated hospitalizations.
The trial is investigating the efficacy, safety, and immunogenicity of mRNA-1273 at the 100mcg dose.